Aeglea BioTherapeutics, which is developing enzymes for rare genetic metabolic diseases and tumors, raised $50 million by offering 5 million shares at $10. It had originally planned to raise $60 million by offering 3.5 million shares at a range of $16 to $18. Aeglea BioTherapeutics plans to list on the Nasdaq under the symbol AGLE. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as lead managers on the deal.
